Pure Red-Cell Aplasia Secondary to Antierythropoietin Antibodies

Publisher Website
Google Scholar
Abstract
The use of recombinant human erythropoietin in patients with kidney disease is widespread and has been associated with few complications. Recent reports have suggested that the incidence of pure red-cell aplasia is increasing among European patients, who are often treated with subcutaneous epoetin alfa (Eprex).1,2 Neutralizing antierythropoietin antibodies were detected in these patients. We describe a case of pure red-cell aplasia in an American patient who was receiving epoetin alfa (Procrit, Ortho Biotech). Antierythropoietin antibodies were found to be neutralizing in vivo and in a murine erythroid cell line.

This publication has 2 references indexed in Scilit: